The effectiveness of using the conjugated pneumococcal vaccine in patients with chronic obstructive pulmonary disease for 3 years

The article presents the results of a study showing prospective clinical and cost-effectiveness of vaccination conjugated pneumococcal vaccine Prevenar 13, with a horizon of 3 years in patients with chronic obstructive pulmonary disease (COPD) compared with patients without vaccination.Material and Methods. The study included 496 male patients who were treated at the Regional Hospital №4 and the city pulmonology center of Chelyabinsk in 2012-2015. The average age of study patients was 61.30±6.92 years. All patients underwent a complete clinical and instrumental study. The degree of dyspnea was assessed by MRC scale. For vaccination the 13-valent pneumococcal conjugate vaccine (PCV13) Prevenar 13 was used.Results and conclusions. Over 3 years in vaccinated patients there was a significant reduction in exacerbations of COPD level 9.6 times decrease in the number of hospital admissions by 7.7 times, improved respiratory function indices were also noted. PCV13 minimizes pro-health system expenditure for the treatment of patients with COPD. These budget savings of 89% in 3 years after vaccination, reached 61.737 rubles per 1 patient.

chronic obstructive pulmonary disease, exacerbation of chronic obstructive pulmonary disease, 13- valent pneumococcal conjugate vaccine, vaccine